Sphaera Pharma has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for its patent application titled ‘Substituted methylformyl reagents and method of using same to modify physicochemical and pharmacokinetic properties of compounds’, for its proprietary platform technology.

Drug Modification Technology (DMT) platform can help address sub-optimal physico-chemical and pharmacokinetic properties of approved drugs and drugs in development.

Sphaera’s technology allows for improved delivery of a drug, parenterally or orally, by improving its pH independent solubility and can be easily implemented for almost any drug. Some applications include development of paediatric formulations and alternate dosing forms for approved drugs.

The company is advancing multiple drugs using this approach through the various stages of pre-clinical and clinical development and expects the first US FDA approved clinical trial in the US with a NCE developed using this technology by a licensee early next year.

“We are very pleased by this development. This not only brings significant credible external validation of the quality of intellectual property developed by us. It also enhances the value of drugs developed using this platform for our current and potential partners. Our DMT platform provides an excellent opportunity for existing generic companies to move up the value chain by rescuing, recovering, re-purposing and re-positioning of drugs,” said Dr. Sundeep Dugar, founder, Sphaera Pharma.